For Healthcare Professionals: Prostate Cancer

The Sidney Kimmel Center for Prostate and Urologic Cancers has more than 30 urologic surgeons, medical oncologists, and physicians from other clinical disciplines who provide an array of prostate cancer treatment options to 3,700 men annually. Recent progress in understanding the biology of prostate malignancies, combined with advances in surgery, radiation therapy, and medical therapies, has made it possible to eliminate most localized prostate cancers, and to substantially extend life for men with metastatic disease.

Refering a Patient

Call 877-284-5246
Mon–Fri, 8:30 AM–5:30 PM, ET

Find an Expert | See Clinical Trials | Request a Pathology Consult

More Science. Less Fear.
It’s Time to Change How the World Treats Cancer.

Learn how we’re making what was impossible yesterday possible today.

Pictured: Peter Scardino, James Eastham & Victor Reuter
Prostate Cancer Information for Your Patients

The Memorial Sloan Kettering approach to diagnosis and treatment of prostate cancer in patient-friendly language

Prediction Tools

Our online nomograms can be used to predict which approaches to treating prostate cancer will result in the greatest benefit. Results can help physicians and patients make important decisions.

Screening Guidelines

Get our recommendations on when and how often men should be screening for ptostate cancer.

E-Publications for Medical Professionals

Stay up-to-date on Memorial Sloan Kettering advances in your areas of interest.

Subscribe to OncoNotes »

Pictured: Dana Rathkopf
Novel Agents Targeting the Androgen Receptor in Castration-Resistant Prostate Cancer

Medical oncologist Dana Rathkopf discusses therapies for metastatic prostate cancer that target the androgen receptor.

Prostate-Specific PET Scans

Medical oncologist Michael Morris describes a technique developed at Memorial Sloan Kettering to image prostate cancer metastases via PET scan.

Radiopharmaceuticals for Prostate Cancer

Medical oncologist Michael Morris describes noninvasive radiopharmaceuticals for prostate cancer–related bone metastases.

Pictured: Dana Rathkopf
Androgen Receptor
PET Scans